局部晚期直肠癌炎症标志物的预测与预后价值(PILLAR):意大利放射治疗与临床肿瘤学协会(AIRO)胃肠道研究组的多中心分析
该多中心回顾性研究纳入2002年1月至2019年12月意大利9个中心的808例局部晚期直肠癌患者,评估基线炎症标志物对病理完全缓解(pCR)、无病生存(DFS)和总生存(OS)的预测与预后价值。多因素分析显示NLR>1.2和SII>500可预测pCR,MLR>0.18和HEI=3是DFS的独立预后因素,MLR>0.35和HEI=3是OS的独立预测因素。作者认为较高的基线复合炎症标志物可预测较低的pCR率和较差的生存结局,并建议前瞻性研究提供更可靠数据以将这些廉价易得的工具整合入临床实践。
要点
- NLR>1.2和SII>500可预测局部晚期直肠癌新辅助放化疗后的病理完全缓解。
- MLR>0.18和HEI=3是DFS的独立预后因素,MLR>0.35和HEI=3是OS的独立预测因素。
- 作者认为较高的基线复合炎症标志物可预测较低的pCR率和较差的生存结局。
核心结论
- 较高的基线复合炎症标志物可作为接受新辅助放化疗的局部晚期直肠癌患者较低pCR率和较差生存结局的预测因素。
研究设计与样本
- 回顾性多中心队列研究,纳入2002年1月至2019年12月意大利9个中心的808例局部晚期直肠癌患者。
- 患者接受长程放疗联合以氟尿嘧啶类为基础±奥沙利铂的化疗,随后手术。
- 基于治疗前血样获取炎症标志物,包括HEI、SII、NLR、PLR和MLR。
主要发现
- pCR率为22%,5年OS为84.0%,5年DFS为63.1%。
- 多因素分析显示NLR cut-off值>1.2和SII cut-off值>500可预测pCR(p分别为0.05和0.009)。
- 除年龄、直肠外淋巴结和放疗剂量外,MLR>0.18(p=0.03)和HEI=3(p=0.05)是DFS的独立预后因素。
- 年龄、放疗剂量、MLR cut-off值>0.35(p=0.028)和HEI=3(p=0.045)是OS的独立预测因素。
关键数值与推荐
- NLR cut-off值>1.2预测pCR的p=0.05。
- SII cut-off值>500预测pCR的p=0.009。
- MLR>0.18是DFS独立预后因素的p=0.03;HEI=3是DFS独立预后因素的p=0.05。
- MLR cut-off值>0.35是OS独立预测因素的p=0.028;HEI=3是OS独立预测因素的p=0.045。
临床怎么用
- 作者认为,来自前瞻性研究的更可靠数据可能促使将这些廉价且易于获取的工具整合入临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients (pts) affected with locally advanced rectal cancer (LARC) may respond differently to neoadjuvant chemoradiotherapy (nCRT). The identification of reliable biomarkers able to predict oncological outcomes could help in the development of risk-adapted treatment strategies. It has been suggested that inflammation parameters may have a role in predicting tumor response to nCRT and survival outcomes and in rectal cancer, but no definitive conclusion can be drawn at present. The aim of the current study is to evaluate the role of baseline inflammatory markers as prognostic and predictive factors in a large multicentric Italian cohort of LARC pts. METHODS: Patients diagnosed with LARC from January 2002 to December 2019 in 9 Italian centers were retrospectively collected. Patients underwent long-course RT with chemotherapy based on fluoropyrimidine ± oxaliplatin followed by surgery. Inflammatory markers were retrieved based on a pre-treatment blood sample including HEI (hemo-eosinophils inflammation index), SII (systemic index of inflammation), NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio) and MLR (monocyte-to-lymphocyte ratio). Outcomes of interest were pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). RESULTS: 808 pts were analyzed. pCR rate was 22 %, 5yOS and 5yDFS were 84.0% and 63.1% respectively. Multivariate analysis identified that a NLR cut-off value >1.2 and SII cut-off value >500 could predict pCR (p = 0.05 and 0.009 respectively). In addition to age, extramesorectal nodes and RT dose, MLR >0.18 (p = 0.03) and HEI = 3 (p = 0.05) were independent prognostic factors for DFS. Finally, age, RT dose, MLR with a cut-off >0.35 (p = 0.028) and HEI = 3 (p = 0.045) were independent predictors of OS. CONCLUSIONS: Higher values of baseline composite inflammatory markers can serve as predictors of lower pCR rates and worse survival outcomes in LARC patients undergoing nCRT. More reliable data from prospective studies could lead to the integration of these inexpensive and easy-to-derive tools into clinical practice.
引用
- Chiloiro G, Romano A, Mariani S, et al. Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) - A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group. Clin Transl Radiat Oncol. 2023. PMID: 36935859. doi:10.1016/j.ctro.2023.100579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。